Terms: = Melanoma AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
5900 results:
1. Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated
Awada G; Dirven I; Schwarze JK; Tijtgat J; Fasolino G; Kockx M; Neyns B
JCO Precis Oncol; 2024 Oct; 8():e2300493. PubMed ID: 39374099
[TBL] [Abstract] [Full Text] [Related]
2. Spitz melanoma with MAP3K8::ABLIM1 rearrangement: a case report with review of the literature.
Sibira R; Vu A; Giubellino A; Murugan P
Diagn Pathol; 2024 Oct; 19(1):133. PubMed ID: 39363234
[TBL] [Abstract] [Full Text] [Related]
3. Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
Di Pietro FR; Marinelli D; Verkhovskaia S; Poti G; Falcone R; Carbone ML; Morelli MF; Zappalà AR; Di Rocco ZC; Morese R; Piesco G; Chesi P; Marchetti P; Failla CM; De Galitiis F
BMC Cancer; 2024 Oct; 24(1):1220. PubMed ID: 39354418
[TBL] [Abstract] [Full Text] [Related]
4. melanoma genomics - will we go beyond braf in clinics?
Mirek J; Bal W; Olbryt M
J Cancer Res Clin Oncol; 2024 Sep; 150(9):433. PubMed ID: 39340537
[TBL] [Abstract] [Full Text] [Related]
5. Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on braf Mutant melanoma Cells and Their Hyaluronic Acid-Based Hydrogel Formulation.
Alfei S; Zuccari G; Athanassopoulos CM; Domenicotti C; Marengo B
Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337557
[TBL] [Abstract] [Full Text] [Related]
6. Sequencing of Checkpoint or braf/MEK Inhibitors on Brain Metastases in melanoma.
Ascierto PA; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Quaglino P; Lebbé C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Gonzalez-Cao M; Minisini AM; De Placido S; Sanmamed MF; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Palmieri G; Dummer R; Sileni VC
NEJM Evid; 2024 Oct; 3(10):EVIDoa2400087. PubMed ID: 39315864
[TBL] [Abstract] [Full Text] [Related]
7. Treatment resistance to melanoma therapeutics on a single cell level.
Yao L; Krasnick BA; Bi Y; Sethuraman S; Goedegebuure S; Weerasinghe A; Wetzel C; Gao Q; Oyedeji A; Mudd J; Wyczalkowski MA; Wendl M; Ding L; Fields RC
Sci Rep; 2024 Sep; 14(1):21915. PubMed ID: 39300183
[TBL] [Abstract] [Full Text] [Related]
8. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
Eggermont AM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Lorigan P; Grebennik D; Kreplere C; Marreaud S; Suciu S; Robert C
Eur J Cancer; 2024 Nov; 211():114327. PubMed ID: 39288737
[TBL] [Abstract] [Full Text] [Related]
9. MEK inhibitors in oncology: a patent review and update (2016 - present).
Suryavanshi A; Vandana ; Shukla YK; Kumar V; Gupta P; Asati V; Mahapatra DK; Keservani RK; Jain SK; Bharti SK
Expert Opin Ther Pat; 2024 Oct; 34(10):963-1007. PubMed ID: 39275922
[TBL] [Abstract] [Full Text] [Related]
10. Expression of
Šitum Čeprnja Z; Kelam N; Ogorevc M; Racetin A; Vukoja M; Čeprnja T; Filipović N; Saraga-Babić M; Vukojević K
Cells; 2024 Aug; 13(17):. PubMed ID: 39273022
[TBL] [Abstract] [Full Text] [Related]
11. TransCell: In Silico Characterization of Genomic Landscape and Cellular Responses by Deep Transfer Learning.
Yeh SJ; Paithankar S; Chen R; Xing J; Sun M; Liu K; Zhou J; Chen B
Genomics Proteomics Bioinformatics; 2024 Jul; 22(2):. PubMed ID: 39240541
[TBL] [Abstract] [Full Text] [Related]
12. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors.
Lim SY; Lin Y; Lee JH; Pedersen B; Stewart A; Scolyer RA; Long GV; Yang JYH; Rizos H
EBioMedicine; 2024 Sep; 107():105308. PubMed ID: 39216232
[TBL] [Abstract] [Full Text] [Related]
13. Brief Communication: Treatment Outcomes for Advanced melanoma of Unknown Primary Compared With melanoma With Known Primary.
Persa OD; Hassel JC; Steeb T; Erdmann M; Karimi B; Stege H; Klespe KC; Schatton K; Tomsitz D; Rübben A; Thiem A; Berking C; Biedermann T
J Immunother; 2024 Nov-Dec 01; 47(9):384-387. PubMed ID: 39206786
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal melanoma Cell Line 92-1.
Gao YU; Wendt S; Krohn S; Alammar M; Junghanss C; Nolte I; Escobar HM
Anticancer Res; 2024 Sep; 44(9):3843-3848. PubMed ID: 39197916
[TBL] [Abstract] [Full Text] [Related]
15. Role of mitochondria and potential of mitochondria-targeted therapy in braf mutant cancer: A review.
Gao Y; Zheng H
Crit Rev Oncol Hematol; 2024 Nov; 203():104484. PubMed ID: 39197669
[TBL] [Abstract] [Full Text] [Related]
16. Molecular Susceptibility and Treatment Challenges in melanoma.
Kolathur KK; Nag R; Shenoy PV; Malik Y; Varanasi SM; Angom RS; Mukhopadhyay D
Cells; 2024 Aug; 13(16):. PubMed ID: 39195270
[TBL] [Abstract] [Full Text] [Related]
17. Multi-omics analysis delineates resistance mechanisms associated with braf inhibition in melanoma cells.
Datta KK; Kore H; Gowda H
Exp Cell Res; 2024 Sep; 442(1):114215. PubMed ID: 39182666
[TBL] [Abstract] [Full Text] [Related]
18. lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III melanoma: Data from the Dutch Cancer Registry.
Aldenhoven L; van Weezelenburg MAS; van den Berkmortel FWPJ; Servaas N; Janssen A; Vissers YLJ; van Haaren ERM; Beets GL; van Bastelaar J
Target Oncol; 2024 Sep; 19(5):735-745. PubMed ID: 39182000
[TBL] [Abstract] [Full Text] [Related]
19. Innovations in Rare Gynecologic Cancer: melanoma, Neuroendocrine, and Low-Grade Serous Ovarian.
Au-Yeung G; MacArthur E; Chan J; Ilenkovan N; Frumovitz M; Fader AN; Gourley C
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431818. PubMed ID: 39177646
[TBL] [Abstract] [Full Text] [Related]
20. Characterization of two melanoma cell lines resistant to braf/MEK inhibitors (vemurafenib and cobimetinib).
Kot M; Simiczyjew A; Wądzyńska J; Ziętek M; Matkowski R; Nowak D
Cell Commun Signal; 2024 Aug; 22(1):410. PubMed ID: 39175042
[TBL] [Abstract] [Full Text] [Related]
[Next]
